NCT02008916 (MEASURE 3) is a Phase 3 clinical trial of Secukinumab in Spondylitis, Ankylosing, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT02008916?

NCT02008916 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT02008916?

Interventions in NCT02008916: Secukinumab, Placebo secukinumab.

What condition does NCT02008916 study?

NCT02008916 studies Spondylitis, Ankylosing.

Is NCT02008916 still recruiting?

NCT02008916 is currently completed. Last updated 8 January 2019.

Are results published for NCT02008916?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-01-08 · How we verify

NCT02008916: MEASURE 3

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients

Completed Phase 3 Results posted Last updated 8 January 2019

What this trial tests

Phase 3 trial testing Secukinumab in Spondylitis, Ankylosing in 226 participants. Completed in 11 December 2017.

Timeline

14 January 2014

Primary endpoint
23 February 2015

11 December 2017

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	226
Start date	14 January 2014
Primary completion	23 February 2015
Estimated completion	11 December 2017
Sites	57 locations across Russia, Greece, Belgium, United Kingdom, Germany, Mexico, Portugal, United States

Drugs / interventions tested

Secukinumab (secukinumab) — full drug profile →
Placebo secukinumab

Conditions studied

Spondylitis, Ankylosing — all drugs for Spondylitis, Ankylosing →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Spondylitis, Ankylosing. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With 20% Improvement in the Assessment of Spondyloarthritis International Society Criteria Scale / ASAS 20 Response Primary · 16 weeks

ASAS 20 response is a validated composite assessment, reflecting the proportion of treated patients who achieve within a defined time frame at least 20% improvement in score in at least 3 of a conventional set of 4 clinical domains relevant to AS and no worsening in the fourth domain. In this study, ASAS 20 was used to assess the efficacy of at least one dose of secukinumab versus placebo.

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	43
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	46
Placebo i.v. and s.c.	28
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	31
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	30
Placebo i.v. and s.c.	48

ASAS 40 Response Secondary · 16 weeks

ASAS 40 response is a validated composite assessment, reflecting the proportion of treated patients who achieve within a defined time frame at least 40% improvement in score in at least 3 of a conventional set of 4 clinical domains relevant to AS and no worsening in the fourth domain. In this study, ASAS 40 was used to assess the efficacy of at least one dose of secukinumab versus placebo.

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	30
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	32
Placebo i.v. and s.c.	16
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	44
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	44
Placebo i.v. and s.c.	60

Serum hsCRP Secondary · Baseline and 16 weeks

Blood levels of C-reactive protein (CRP), an acute phase reactant, are indicative of inflammation and of its severity, and can be used to monitor treatment response. A high sensitivity CRP (hsCRP) test was implemented in this study, to assess the efficacy of at least one dose of secukinumab versus placebo in reducing AS elicited systemic inflammation over the time.

Baseline

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	15.79	± 21.075
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	11.08	± 13.285
Placebo i.v. and s.c.	13.91	± 19.999

Week 16

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	7.68	± 13.277
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	4.34	± 5.433
Placebo i.v. and s.c.	15.34	± 21.694

Change from Baseline to Week 16

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	-8.06	± 21.132
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	-6.75	± 13.778
Placebo i.v. and s.c.	0.57	± 11.629

ASAS 5/6 Response Secondary · 16 weeks

ASAS 5/6 response is a validated composite assessment, reflecting the proportion of treated patients who achieve within a defined time frame at least 20% improvement in score in at least 5 of a conventional set of 6 clinical domains relevant to AS and no worsening in the remaining domain. In this study, ASAS 5/6 was used to assess the efficacy of at least one dose of secukinumab versus placebo.

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	31
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	30
Placebo i.v. and s.c.	11
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	43
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	46
Placebo i.v. and s.c.	65

Bath Ankylosing Spondylitis Disease Activity Index / BASDAI Secondary · Baseline and 16 weeks

BASDAI is a validated assessment tool using 0 through 10 scales (0 indicating "no problem" and 10 indicating "worst problem"), to characterise six clinical domains pertaining to five major symptoms of AS perceived by the patients. Computed composite scores of 4 or greater indicate suboptimal disease control. In this study, the BASDAI index was used to assess the efficacy of at least one dose of secukinumab versus placebo.

Baseline

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	6.958	± 1.3913
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	6.963	± 1.3766
Placebo i.v. and s.c.	6.907	± 1.2600

Week 16

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	4.451	± 2.5623
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	4.178	± 2.7038
Placebo i.v. and s.c.	5.369	± 2.2574

Change from Baseline to Week 16

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	-2.548	± 2.4559
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	-2.796	± 2.6374
Placebo i.v. and s.c.	-1.590	± 2.0084

Number of Participants With Successful Self-administration (to Measure Usability of Pre-filled Syringe) Secondary · Week 8 and Week 12

Successful self-administration is defined as success in steps P8 (Removed Needle Cap from Safety Syringe), P10 (Pinched the Skin at Injection Site), P11 (Inserted the Needle into Skin), P12 (Held onto the Finger Flange), P13 (Fully Depressed Plunger until End Point), and P14 (Held Plunger Down and Syringe in Place) of the Instructions for Use, as observed by the site staff at applicable visits.

Self-administration Week 8

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	72
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	73
Placebo i.v. and s.c.	71
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	0
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	0
Placebo i.v. and s.c.	1
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	2
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	3
Placebo i.v. and s.c.	3

Self-administration Week 12

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	74
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	75
Placebo i.v. and s.c.	72
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	0
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	0
Placebo i.v. and s.c.	0
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	0
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	1
Placebo i.v. and s.c.	3

Pre-filled Syringe Possible Hazard Secondary · Week 8 and Week 12

The number and percentage of subjects who experience any of the defined possible hazards are summarized, as defined in the Possible Hazard assessment check list and as observed by the site staff at applicable visits.

Week 8:Was needle stick in a critical area?

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	0
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	0
Placebo i.v. and s.c.	0
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	73
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	73
Placebo i.v. and s.c.	72
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	1
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	3
Placebo i.v. and s.c.	3

Week 8: Was needle stick in a non-critical area?

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	2
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	5
Placebo i.v. and s.c.	3
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	71
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	68
Placebo i.v. and s.c.	69
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	1
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	3
Placebo i.v. and s.c.	3

Week 8: Was any part of the device swallowed?

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	0
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	0
Placebo i.v. and s.c.	0
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	73
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	73
Placebo i.v. and s.c.	72
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	1
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	3
Placebo i.v. and s.c.	3

Week 8: Was allergic reaction to device noticed?

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	0
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	0
Placebo i.v. and s.c.	0
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	73
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	73
Placebo i.v. and s.c.	72
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	1
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	3
Placebo i.v. and s.c.	3

Week 8: Was pain increased due to bent needle?

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	0
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	0
Placebo i.v. and s.c.	0
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	73
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	73
Placebo i.v. and s.c.	72
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	1
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	3
Placebo i.v. and s.c.	3

Week 8: Was there breakage of device observed?

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	0
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	0
Placebo i.v. and s.c.	0
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	73
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	73
Placebo i.v. and s.c.	72
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	1
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	3
Placebo i.v. and s.c.	3

Week 8:Was swallowing of debris observed?

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	0
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	0
Placebo i.v. and s.c.	0
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	73
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	73
Placebo i.v. and s.c.	72
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	1
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	3
Placebo i.v. and s.c.	3

Week 8:Was any other problem observed?

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	1
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	0
Placebo i.v. and s.c.	0
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	72
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	73
Placebo i.v. and s.c.	72
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	1
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	3
Placebo i.v. and s.c.	3

Prefilled Syringe Patient Satisfaction Assessment Secondary · Baseline, weeks 8, 12 and 16

The self-injection assessment questionnaire (SIAQ) measures overall patient experience with subcutaneous self-injection at applicable visits. Domain scores ranging from 0 (worst experience) to 10 (best experience) are presented: Feeling about injections, Self-confidence, Satisfaction with self-injection.

Week 0: Feeling about injections

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	7.97	± 1.946
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	7.66	± 2.369
Placebo i.v. and s.c.	8.01	± 1.927

Week 8: Feeling about injections

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	7.96	± 2.538
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	7.68	± 2.296
Placebo i.v. and s.c.	8.24	± 2.082

Week 12: Feeling about injections

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	8.45	± 1.968
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	7.93	± 2.201
Placebo i.v. and s.c.	8.25	± 1.997

Week 16: Feeling about injections

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	8.15	± 2.337
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	7.99	± 2.269
Placebo i.v. and s.c.	8.41	± 2.037

Week 0: Self-confidence

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	6.27	± 2.811
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	6.66	± 2.315
Placebo i.v. and s.c.	6.52	± 2.273

Week 8: Self-confidence

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	7.08	± 2.520
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	6.66	± 2.855
Placebo i.v. and s.c.	7.41	± 2.198

Week 12: Self-confidence

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	7.01	± 2.603
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	7.28	± 2.231
Placebo i.v. and s.c.	7.42	± 2.230

Week 16: Self-confidence

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	7.51	± 2.388
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	7.23	± 2.566
Placebo i.v. and s.c.	7.64	± 2.192

ASAS Partial Remission Secondary · 16 weeks

ASAS partial remission is a composite assessment, reflecting the proportion of treated patients who achieve within a defined time frame a value not above 2 units in each of the 4 ASAS domains on a scale of 10. In this study, ASAS partial remission was used to assess the efficacy of at least one dose of secukinumab versus placebo.

Group	Value	95% CI
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	7
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	16
Placebo i.v. and s.c.	1
Secukinumab 10 mg/kg i.v. / 150 mg s.c.	67
Secukinumab 10 mg/kg i.v. / 300 mg s.c.	60
Placebo i.v. and s.c.	75

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit up to approximately 3 years.. Reporting threshold: 2%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Any Secukinumab 150 mg

Serious: 11/110 (10%)

Deaths: 0/110

Any Secukinumab 300 mg

Serious: 11/113 (10%)

Deaths: 0/113

Any Secukinumab

Serious: 22/223 (10%)

Deaths: 0/223

Placebo

Serious: 1/75 (1%)

Deaths: 0/75

Serious adverse events (37 terms)

Reaction	System	Any Secukinumab 150 mg	Any Secukinumab 300 mg	Any Secukinumab	Placebo
Urinary tract infection	Infections and infestations	—	—	—	—
Coronary artery disease	Cardiac disorders	—	—	—	—
Myocardial infarction	Cardiac disorders	—	—	—	—
Sinus node dysfunction	Cardiac disorders	—	—	—	—
Supraventricular extrasystoles	Cardiac disorders	—	—	—	—
Supraventricular tachycardia	Cardiac disorders	—	—	—	—
Vertigo	Ear and labyrinth disorders	—	—	—	—
Cataract	Eye disorders	—	—	—	—
Iridocyclitis	Eye disorders	—	—	—	—
Vogt-Koyanagi-Harada syndrome	Eye disorders	—	—	—	—
Haemorrhoids	Gastrointestinal disorders	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—
Fatigue	General disorders	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—
Pyelonephritis acute	Infections and infestations	—	—	—	—
Ankle fracture	Injury, poisoning and procedural complications	—	—	—	—
Cervical vertebral fracture	Injury, poisoning and procedural complications	—	—	—	—
Fall	Injury, poisoning and procedural complications	—	—	—	—
Hand fracture	Injury, poisoning and procedural complications	—	—	—	—
Limb injury	Injury, poisoning and procedural complications	—	—	—	—
Rib fracture	Injury, poisoning and procedural complications	—	—	—	—
Tibia fracture	Injury, poisoning and procedural complications	—	—	—	—
Ankylosing spondylitis	Musculoskeletal and connective tissue disorders	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—
Osteoarthritis	Musculoskeletal and connective tissue disorders	—	—	—	—

Other adverse events (55 terms — click to expand)

Reaction	System	Any Secukinumab 150 mg	Any Secukinumab 300 mg	Any Secukinumab	Placebo
Nasopharyngitis	Infections and infestations	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—
Headache	Nervous system disorders	—	—	—	—
Bronchitis	Infections and infestations	—	—	—	—
Respiratory tract infection	Infections and infestations	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—
Oropharyngeal pain	Respiratory, thoracic and mediastinal disorders	—	—	—	—
Influenza	Infections and infestations	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—
Hypertension	Vascular disorders	—	—	—	—
Rhinitis	Infections and infestations	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—
Fatigue	General disorders	—	—	—	—
Pharyngitis	Infections and infestations	—	—	—	—
Sinusitis	Infections and infestations	—	—	—	—
Uveitis	Eye disorders	—	—	—	—
Abdominal pain upper	Gastrointestinal disorders	—	—	—	—
Tonsillitis	Infections and infestations	—	—	—	—
Ankylosing spondylitis	Musculoskeletal and connective tissue disorders	—	—	—	—
Muscle spasms	Musculoskeletal and connective tissue disorders	—	—	—	—
Spinal pain	Musculoskeletal and connective tissue disorders	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—
Hypercholesterolaemia	Metabolism and nutrition disorders	—	—	—	—
Arthritis	Musculoskeletal and connective tissue disorders	—	—	—	—
Osteoarthritis	Musculoskeletal and connective tissue disorders	—	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—
Migraine	Nervous system disorders	—	—	—	—
Depression	Psychiatric disorders	—	—	—	—
Food poisoning	Gastrointestinal disorders	—	—	—	—
Toothache	Gastrointestinal disorders	—	—	—	—
Pulpitis dental	Infections and infestations	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—
Gastritis	Gastrointestinal disorders	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—
Conjunctivitis	Infections and infestations	—	—	—	—
Gastroenteritis viral	Infections and infestations	—	—	—	—

Most-reported serious reactions: Urinary tract infection, Coronary artery disease, Myocardial infarction, Sinus node dysfunction, Supraventricular extrasystoles, Supraventricular tachycardia, Vertigo, Cataract.

Data from ClinicalTrials.gov NCT02008916 adverse events section.

Sponsor's own description

The purpose of this study was to generate 16-week efficacy data, as well as up to 3-year efficacy, safety and tolerability data in subjects with active AS despite current or previous NSAID, DMARD and/or anti-TNF therapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
Pavelka K, Kivitz A, Dokoupilova E, Blanco R, et al · · 2017 · cited 163× · PMID 29273067 · DOI 10.1186/s13075-017-1490-y
Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
Elewski BE, Baddley JW, Deodhar AA, Magrey M, et al · · 2021 · cited 51× · PMID 33001147 · DOI 10.1001/jamadermatol.2020.3257
Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies.
Deodhar AA, Miceli-Richard C, Baraliakos X, Marzo-Ortega H, et al · · 2020 · cited 35× · PMID 32352653 · DOI 10.1002/acr2.11139
Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study.
Pavelka K, Kivitz AJ, Dokoupilova E, Blanco R, et al · · 2020 · cited 33× · PMID 31957970 · DOI 10.1002/acr2.11102
Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications.
Merola JF, McInnes IB, Deodhar AA, Dey AK, et al · · 2022 · cited 32× · PMID 35305260 · DOI 10.1007/s40744-022-00434-z
Secukinumab for ankylosing spondylitis and psoriatic arthritis.
Lubrano E, Perrotta FM. · · 2016 · cited 29× · PMID 27799780 · DOI 10.2147/tcrm.s100091
Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis.
Deodhar A, Gladman DD, McInnes IB, Spindeldreher S, et al · · 2020 · cited 21× · PMID 31203228 · DOI 10.3899/jrheum.190116
Practical considerations in clinical strategy to support the development of injectable drug-device combination products for biologics.
Li Z, Li Z, Easton R. · · 2018 · cited 21× · PMID 29035675 · DOI 10.1080/19420862.2017.1392424

Verify or expand the search:

Other trials of Secukinumab

Trials testing the same drug.

NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07477795 — Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients · Phase 2 · not yet recruiting
NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
NCT07243782 — Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cose · recruiting
NCT06751238 — Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in · Phase 1 · recruiting

Other recruiting trials for Spondylitis, Ankylosing

Currently open trials in the same condition.

NCT06842316 — Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases · recruiting
NCT05879419 — Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases · Phase 4 · active not recruiting
NCT05647577 — The Relationship Between Inflammatory ARTritis and CArdiac DIseAse · active not recruiting
NCT04731831 — Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response. · recruiting
NCT01422694 — Natural History and Development of Spondyloarthritis · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02008916 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 8 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02008916.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing